Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $40.30M
• Dividend Yield: 8%
• Average Volume (3M): 12.06K
• Price to Earnings (P/E): 380.0
• Beta (1Y): >-0.01
• Revenue Growth: 1.10%
• EPS Growth: 98.13%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): 0.04
• Shares Outstanding: 8,057,150
• 10 Day Avg. Volume: 10,096
• 30 Day Avg. Volume: 12,058
• PEG Ratio: 0.57
• Price to Book (P/B): -2.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.91
• Enterprise Value/Market Cap: 1.20
• Enterprise Value/Revenue: 0.38
• Enterprise Value/Gross Profit: 1.98
• Enterprise Value/Ebitda: 137.87
• 1Y Price Target: $8.50
• Price Target Upside: 70.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $5.00 ▲(0.00%Upside)

Cryo-Cell International's overall stock score is driven by significant financial and operational challenges. The company's financial instability is highlighted by negative equity and high operational costs, despite strong cash flow management. Technical analysis shows weak market momentum, and corporate events present additional risks, such as license termination and dividend reduction. The high dividend yield offers some appeal but is overshadowed by broader financial and strategic concerns.

Positive Factors

Business Model

Cryo-Cell's core business of processing and storing stem cells has high margins and mostly recurring revenue, contributing to its financial attractiveness.

Dividend Yield

The company maintains a high dividend yield of 18.1%, which is attractive to investors seeking regular income.

Financial Performance

Cryo-Cell International reported a strong EBITDA performance, demonstrating resilience despite a slight decline in overall revenue.

Negative Factors

Litigation

The ongoing arbitration against Duke University could potentially impact the company's financial position, with management believing damages could exceed $100M.

Litigation Costs

Higher expenses are expected due to litigation costs and Duke royalty expenses being accrued.

Revenue Growth

There is a decrease in new business processed by 18%, impacting overall growth.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

How the Company Makes Money

Cryo-Cell International primarily generates revenue through the fees it charges for its cryopreservation services. The company collects an initial processing fee when customers enroll in its storage program for umbilical cord blood and tissue. In addition to this upfront charge, Cryo-Cell earns recurring revenue from annual storage fees paid by clients who maintain their stored specimens with the company. These long-term storage contracts contribute significantly to the company's financial stability. Furthermore, Cryo-Cell may also have partnerships with healthcare providers and hospitals that refer clients to its services, enhancing its market reach and customer base.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International's financial performance shows a stable revenue base but significant profitability and balance sheet challenges. The income statement indicates high operational costs impacting net profit. The balance sheet is under pressure with negative equity, highlighting financial instability. However, the cash flow statement provides a silver lining with strong cash generation capabilities, suggesting potential for operational turnaround with improved cost management and strategic financial restructuring.

Income Statement

The income statement shows stable revenue with slight growth over the years, but profitability margins are concerning. The TTM gross profit margin is robust at 76.2%, yet the net profit margin is very low at 0.8%, indicating high operational costs. EBIT and EBITDA margins are 11.9% and 6.9% respectively, which show operational challenges. Revenue growth is modest, but profitability issues suggest room for efficiency improvements.

Balance Sheet

The balance sheet reveals significant financial risks with negative stockholders' equity of -$15.56 million, highlighting insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, indicating a leveraged position. Total assets are declining, and the equity ratio is negative, emphasizing financial instability. Overall, the balance sheet suggests urgent need for capital restructuring.

Cash Flow

Cash flow analysis shows strong operating cash flow relative to net income, with a TTM operating cash flow of $6.26 million and a free cash flow of $5.67 million. The free cash flow growth is positive, reflecting effective cash management despite low net income. The company has managed to maintain positive free cash flow, providing some financial flexibility amidst profitability challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.99M	31.34M	30.34M	28.88M	31.15M
Gross Profit	24.04M	22.90M	21.54M	19.90M	21.49M
EBITDA	1.42M	-10.42M	6.65M	5.32M	7.22M
Net Income	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet
Total Assets	64.68M	61.22M	64.89M	60.66M	46.20M
Cash, Cash Equivalents and Short-Term Investments	3.50M	980.25K	1.72M	8.34M	10.45M
Total Debt	12.93M	10.90M	11.61M	2.82M	6.24M
Total Liabilities	77.89M	72.25M	66.41M	56.48M	48.87M
Stockholders Equity	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow
Free Cash Flow	3.61M	1.28M	-8.60M	974.92K	8.02M
Operating Cash Flow	6.01M	8.92M	8.57M	7.93M	8.47M
Investing Cash Flow	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
Financing Cash Flow	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Neutral. The current price of 5 is above the 20-day moving average (MA) of 4.95, below the 50-day MA of 5.01, and below the 200-day MA of 6.26, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 39.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	69 Neutral	$17.41M	12.26	6.16%	―	35.25%	175.21%
PIII	57 Neutral	$52.25M	―	-131.17%	―	9.79%	-47.01%
Sector *	52 Neutral	$7.65B	0.16	-63.14%	2.08%	16.38%	0.82%
DCGO	51 Neutral	$144.69M	12.68	-0.21%	―	-26.00%	-103.18%
CCEL	49 Neutral	$40.30M	380.00	93.38%	8.00%	1.10%	98.13%
MODV	48 Neutral	$43.64M	―	-951.52%	―	-0.70%	-2.38%
CCM	39 Underperform	$22.79M	―	14.03%	―	-29.82%	-2.57%

Cryo-Cell International Corporate Events

Cryo-Cell Faces License Termination by Duke University

Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.

The most recent analyst rating on (CCEL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Cryo-Cell International Declares Reduced Quarterly Dividend

On May 7, 2025, Cryo-Cell International‘s Board of Directors declared a reduced quarterly cash dividend of $0.15 per share, reflecting the current economic environment and capital allocation alternatives. This decision, announced on May 8, 2025, may impact shareholder returns and indicates a cautious approach to financial management amid uncertain economic conditions.